A number of other research firms also recently issued reports on CRSP. Barclays raised their price target on Crispr Therapeutics from $59.00 to $62.00 and gave the stock an overweight rating in a research note on Tuesday, July 30th. BTIG Research raised their price target on Crispr Therapeutics from $51.00 to $59.00 and gave the stock a positive rating in a research note on Tuesday, July 30th. Evercore ISI began coverage on Crispr Therapeutics in a research note on Thursday, April 11th. They issued an outperform rating on the stock. Canaccord Genuity began coverage on Crispr Therapeutics in a research note on Friday, July 26th. They issued a buy rating and a $72.00 price target on the stock. Finally, Jefferies Financial Group began coverage on Crispr Therapeutics in a research note on Thursday, August 1st. They issued a buy rating and a $64.00 price target on the stock. Two analysts have rated the stock with a sell rating, five have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $58.00.
CRSP stock opened at $45.00 on Friday. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $59.00. The company has a current ratio of 13.96, a quick ratio of 13.96 and a debt-to-equity ratio of 0.10. The business has a fifty day moving average price of $48.24.
In related news, President Rodger Novak sold 50,000 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $45.00, for a total value of $2,250,000.00. Following the transaction, the president now directly owns 898,007 shares of the company’s stock, valued at approximately $40,410,315. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Lawrence Otto Klein sold 20,000 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $50.02, for a total value of $1,000,400.00. Following the completion of the transaction, the insider now directly owns 31,579 shares in the company, valued at $1,579,581.58. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 140,000 shares of company stock worth $6,670,400. 21.40% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Valeo Financial Advisors LLC raised its holdings in Crispr Therapeutics by 71.4% during the first quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock valued at $26,000 after acquiring an additional 302 shares during the period. Flagship Harbor Advisors LLC raised its holdings in Crispr Therapeutics by 22.1% during the first quarter. Flagship Harbor Advisors LLC now owns 3,309 shares of the company’s stock valued at $118,000 after acquiring an additional 600 shares during the period. Creative Planning raised its holdings in Crispr Therapeutics by 4.7% during the first quarter. Creative Planning now owns 15,486 shares of the company’s stock valued at $553,000 after acquiring an additional 695 shares during the period. BNP Paribas Arbitrage SA bought a new stake in Crispr Therapeutics during the second quarter valued at about $41,000. Finally, Commonwealth Equity Services LLC raised its holdings in Crispr Therapeutics by 5.9% during the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock valued at $839,000 after acquiring an additional 986 shares during the period. 51.71% of the stock is currently owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Why do companies pay special dividends?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.